Michael Rape is a Professor and Head of the Division of Molecular Therapeutics at UC Berkeley and an Investigator at the Howard Hughes Medical Institute. They co-founded Nurix Tx and Lyterian Tx, and are a member of the Scientific Advisory Board for Vicinitas Therapeutics and Monte Rosa Therapeutics. Michael obtained their degree summa cum laude from the Max Planck Institute of Biochemistry in Germany from 1999 to 2002. Since 2021, they have served as an iPartner at The Column Group.
This person is not in the org chart
This person is not in any teams
This person is not in any offices